388 related articles for article (PubMed ID: 22548922)
1. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study.
Gu R; Jia W; Zeng Y; Rao N; Hu Y; Li S; Wu J; Jin L; Chen L; Long M; Chen K; Chen L; Xiao Q; Wu M; Song E; Su F
BMC Cancer; 2012 May; 12():161. PubMed ID: 22548922
[TBL] [Abstract][Full Text] [Related]
2. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.
; Pagani O; Gelber S; Price K; Zahrieh D; Gelber R; Simoncini E; Castiglione-Gertsch M; Coates AS; Goldhirsch A
Ann Oncol; 2004 Dec; 15(12):1749-59. PubMed ID: 15550579
[TBL] [Abstract][Full Text] [Related]
3. A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis.
Hong J; Huang J; Shen L; Zhu S; Gao W; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
BMC Cancer; 2020 Jul; 20(1):663. PubMed ID: 32677982
[TBL] [Abstract][Full Text] [Related]
4. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.
Holli K; Valavaara R; Blanco G; Kataja V; Hietanen P; Flander M; Pukkala E; Joensuu H
J Clin Oncol; 2000 Oct; 18(20):3487-94. PubMed ID: 11032589
[TBL] [Abstract][Full Text] [Related]
6. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials.
Zhou WB; Ding Q; Chen L; Liu XA; Wang S
Breast Cancer Res Treat; 2011 Aug; 128(3):625-31. PubMed ID: 21553116
[TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
[TBL] [Abstract][Full Text] [Related]
8. Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients.
Bertelli G; Queirolo P; Vecchio S; Angiolini C; Bergaglio M; Del Mastro L; Signorini A; Valenzano M; Venturini M
Anticancer Res; 2000; 20(5C):3659-61. PubMed ID: 11268435
[TBL] [Abstract][Full Text] [Related]
9. Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.
Ekholm M; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Rydén L;
Eur J Cancer; 2019 Mar; 110():53-61. PubMed ID: 30769227
[TBL] [Abstract][Full Text] [Related]
10. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM;
J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.
Pyrhönen S; Ellmén J; Vuorinen J; Gershanovich M; Tominaga T; Kaufmann M; Hayes DF
Breast Cancer Res Treat; 1999 Jul; 56(2):133-43. PubMed ID: 10573106
[TBL] [Abstract][Full Text] [Related]
12. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
13. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Francis PA; Pagani O; Fleming GF; Walley BA; Colleoni M; Láng I; Gómez HL; Tondini C; Ciruelos E; Burstein HJ; Bonnefoi HR; Bellet M; Martino S; Geyer CE; Goetz MP; Stearns V; Pinotti G; Puglisi F; Spazzapan S; Climent MA; Pavesi L; Ruhstaller T; Davidson NE; Coleman R; Debled M; Buchholz S; Ingle JN; Winer EP; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Goldhirsch A; Regan MM;
N Engl J Med; 2018 Jul; 379(2):122-137. PubMed ID: 29863451
[TBL] [Abstract][Full Text] [Related]
14. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
[TBL] [Abstract][Full Text] [Related]
15. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Ahmed I; Piper T; Salunga R; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
Ann Oncol; 2019 Nov; 30(11):1776-1783. PubMed ID: 31504126
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer.
Kimura M; Tominaga T; Kimijima I; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
Breast Cancer; 2014 May; 21(3):275-83. PubMed ID: 22968626
[TBL] [Abstract][Full Text] [Related]
17. Low-grade endometrial stromal sarcoma developing in a postmenopausal woman under toremifene treatment for breast cancer.
Kashiyama T; Oda K; Kawana K; Arimoto T; Kanetaka Y; Takazawa Y; Maeda D; Nakagawa S; Yano T; Kozuma S
J Obstet Gynaecol Res; 2013 Jan; 39(1):424-9. PubMed ID: 22690656
[TBL] [Abstract][Full Text] [Related]
18. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
19. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer.
Love RR; Duc NB; Allred DC; Binh NC; Dinh NV; Kha NN; Thuan TV; Mohsin SK; Roanh le D; Khang HX; Tran TL; Quy TT; Thuy NV; Thé PN; Cau TT; Tung ND; Huong DT; Quang le M; Hien NN; Thuong L; Shen TZ; Xin Y; Zhang Q; Havighurst TC; Yang YF; Hillner BE; DeMets DL
J Clin Oncol; 2002 May; 20(10):2559-66. PubMed ID: 12011136
[TBL] [Abstract][Full Text] [Related]
20. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
Lewis JD; Chagpar AB; Shaughnessy EA; Nurko J; McMasters K; Edwards MJ
Cancer; 2010 May; 116(10):2307-15. PubMed ID: 20209619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
